Podcasts about actinic

Nascentmc.com for medical writing assistance for your company. Visit learnAMAstyle.com for free downloads on medical writing and editing Klisyri for Actinic Keratosis: The FDA has approved tirbanibulin (Klisyri) for treating actinic keratosis (AK) on larger areas of the face or scalp, up to 100 cm². Previously approved for areas up to 25 cm² in December 2020, tirbanibulin is now available in a 350 mg package size for a 5-day topical treatment. Actinic keratosis is the most common pre-cancerous dermatological condition in the US, and this approval was based on a Phase 3 clinical study showing consistent safety and effectiveness for larger treatment areas. MDMA for PTSD: An FDA advisory panel voted 10-1 against endorsing MDMA for PTSD treatment due to flawed study data, questionable research practices, and significant drug risks. The FDA will make its final decision on August 11, but the panel's negative feedback might influence a denial. This decision could impact the approval and acceptance of other psychedelics like LSD and psilocybin for medical use. Arexvy for RSV: The FDA has approved the RSV vaccine AREXVY for preventing RSV lower respiratory tract disease in adults aged 50-59 at increased risk. Initially approved in May 2023 for adults aged 60 and older, AREXVY combines a recombinant RSV glycoprotein with an adjuvant. The approval followed a Phase III trial showing the vaccine's immune response and safety in the targeted age group. Rytelo for MDS: The FDA has approved imetelstat (RYTELO) for treating low- to intermediate-1 risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. Imetelstat, a telomerase inhibitor, demonstrated significant improvements in transfusion independence and hemoglobin levels in the IMerge Phase 3 trial. The approval was granted to Geron Corporation. Firdapse for LEMS: The FDA has approved an increased dose of amifampridine (Firdapse) from 80 mg to 100 mg for treating Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients over 45 kg. Initially approved in 2018 for adults, and expanded to include children as young as 6 in 2022, the increased dose approval was based on clinical trials showing significant improvements in muscle strength. The approval was granted to Catalyst Pharmaceuticals. Nascentmc.com for medical writing assistance for your company. Visit learnAMAstyle.com for free downloads on medical writing and editing

Actinic keratoses are the second most common reason patients visit the dermatologist. In the final podcast in this 3-part educational program, Dr. Neal Bhatia discusses tips and provides advice for AK management, including treatment, reimbursement, and more. Here's Dr. Bhatia

Actinic keratosis (AK) – also commonly known as solar keratosis – is a very common dermatological presentation in primary care, affecting large numbers of older people. It has the capacity to transform into a malignant lesion if untreated. In this podcast, Dr Roger Henderson looks at who is most at risk of AK, how it should be diagnosed, what treatment options are available, and when to consider referral to secondary care.

STUDIES REFERENCED   PATHOLOGY OF NON SCARRING AND SCARRING ALOPECIA   Amanda Araujo Dos Reis Botega et al. Scarring versus Non-Scarring Alopecia: An Interobserver Histopathological Reproducibility Study Skin Appendage Disord. 2023 Jan;9(1):34-41. doi: 10.1159/000526966. Epub 2022 Nov 25.     HYDROXYCHLOROQUINE AND RETINOPATHY RISK   Ronald B Melles RB et al. Hydroxychloroquine Dose and Risk for Incident Retinopathy : A Cohort Study. Ann Intern Med. 2023 Jan 17.   LOW DOSE NALTREXONE IN LICHEN PLANOPILARIS   Lajevardi et al. The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled trial. J Dermatol Treat. Jun 2020   Hamel RK et al. Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study. Cureus Jan 2023.   Toledo-Pastrana et al. Perifollicular Erythema as a Trichoscopy Sign of Progression in Frontal Fibrosing Alopecia. Int J Trichology. 2013 Jul-Sep; 5(3): 151–153.     ACTINIC LICHEN PLANOPILARIS Lalagianni N et al. Actinic lichen planopilaris: a new variant of lichen planopilaris triggered by ultraviolet radiation. Clin Exp Dermatol. 2023 Feb 2;48(2):158-160.     FOLLICULITIS DECALVANS MICROBIOME STUDIES   Moreno-Arrones OM et al. Folliculitis decalvans has a heterogeneous microbiological signature and impaired immunological response. Dermatology. 2023 Jan 30.   Moreno-Arrones et al. Folliculitis decalvans microbiologic signature is specific for disease clinical phenotype. J Am Acad Dermatol. 2021 Nov;85(5):1355-1357.     TNF INHIBITORS IN DISSECTING CELLULITIS Alzahrani M et al. Treatment of dissecting cellulitis of the scalp with tumor necrosis factor inhibitors: a retrospective multicenter STUDY. Clin Exp Dermatol. 2023 Jan 26;llad036.

Actinic keratoses are the second most common reason patients visit the dermatologist. In the second podcast of this educational program, Dr. Todd Schlesinger, Medical Director, Dermatology and Laser Center of Charleston and Fellow, American Society for Mohs Surgery, discusses new and emerging topical treatments for AKs, including photodynamic therapies, topical agents, and more.

Actinic keratoses are the second most common reason patients visit the dermatologist. In the first podcast of this educational program, Dr. Deborah Sarnoff, Clinical Professor of Dermatology, NYU, and President of the Skin Cancer Foundation, discusses the clinical characteristics of AK, including symptoms, histology, and risk for SCC development.

Skin aging is more than cosmetic. In addition to overall thinning, wrinkles, and pigmentary changes, skin becomes fragile and can bruise and tear more easily. In the second podcast in this 3-part series that addresses aging skin and improving skin health, board-certified dermatologists, Dr. Roger Ceilley and Dr. Joel Schlessinger discuss the pathology of actinic purpura, including social impact and strategies for reducing risk. Here's Drs. Ceilley and Schlessinger.

Learn more about this potentially malignant disease and know how to protect yourself. Do you want to know more about oral diseases? Follow us on Instagram @doencasdeboca https://www.instagram.com/doencasdeboca/

Three dermatology residents — Dr. Elisabeth Tracey, Dr. Julie Croley, and Dr. Daniel Mazori — discuss tips for clear communication with patients in this special resident takeover of the podcast. Beginning at 6:11, they talk about challenges with topical therapies and setting expectations with patients. “We, as dermatologists, can optimize patient management by being effective communicators,” said Dr. Croley. They provide communication strategies for improving compliance with therapy and ensuring patients have the correct instructions, as well as clarifying patient misconceptions and the importance of maintenance treatment. We also bring you the latest in dermatology news and research: 1. Topical ruxolitinib looks good for facial vitiligo in phase 2 study. About half of patients on the two highest doses had a 50% improvement after 6 months of treatment. 2. Patients concerned about clinician burnout. Almost three-quarters of Americans are concerned about burnout among health care professionals. 3. Antimalarial may be effective, safe for erosive oral lichen planus. Hydroxychloroquine sulfate may be an effective and relatively safe treatment option for moderate to severe oral lichen planus. Things you will learn in this episode: Review expectations of therapy with patients, such as an intense inflammatory response to topical 5-fluorouracil for actinic keratosis, to ensure that patients remain compliant with the therapy but also feel they can trust you as their physician. If patients are hesitant to use topical minoxidil because they are concerned with the length of time they’ll have to use it, use a metaphor for another lifelong commitment such as brushing your teeth. “What I started actually doing is calling topical minoxidil toothpaste for your hair,” said Dr. Mazori. Talk to patients about spot-treating with acne or applying topical medication appropriately for psoriasis. “A particular challenge in dermatology with topical medications is not just whether or not they use it or pick up the prescription but how they use it,” said Dr. Tracey. Talk to patients about underapplication of sunscreen. Recommend a physical blocker if patients express concerns about systemic absorption. Write down instructions to ensure patients have the relevant information. The teach-back method of communicating with patients often is taught in medical school and ensures that the patients have understood what you’ve said, but it doesn’t ensure that they retained it. Strategies such as having medical students write the instructions or copying notes from your electronic medical record to print for patients can help save time. Emphasize the importance of maintenance treatment for conditions such as intertrigo, seborrheic dermatitis, or onychomycosis to prevent recurrence. Give patients both the trade name and generic name to ensure they use the correct medication. Hosts: Elizabeth Mechcatie, Terry Rudd Guests: Elisabeth (Libby) Tracey, MD (Cleveland Clinic Foundation); Julie Ann Amthor Croley, MD (University of Texas Medical Branch at Galveston); and Daniel R. Mazori, MD (State University of New York, Brooklyn). Show notes by Melissa Sears, Alicia Sonners, and Elizabeth Mechcatie.   You can find more of our podcasts at http://www.mdedge.com/podcasts.    Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeDerm

In this first episode of the new Dermatology Weekly podcast, Dr. Vincent DeLeo talks with Dr. Daniel Siegel and Ramiz Hamid about indoor tanning behaviors among adolescents, and they outline tips for communicating with patients about the harmful effects of tanning. You can read their related article on MDedge Dermatology: https://bit.ly/2Jpetpf. We also bring you the latest in dermatology news and research: 1. Fluorouracil beats other actinic keratosis treatments in head-to-head trial. https://bit.ly/2SNmWC5 2. Match Day 2019: Dermatology steps up growth after slow 2018. https://bit.ly/2unA8Ud 3. Don't miss baby scabies. https://bit.ly/2Tkd0jF Contact us: podcasts@mdedge.com Twitter: @MDedgeDerm          

Actinic keratoses are premalignant lesions that occur in sun exposed skin. 25% of Americans will develop these. Treatment can be medical, with 5FU or Picato, or surgical with cryotherapy or surgery. We discuss these "lesions" as well as a new treatment for chest actinic keratoses. My guest was Dr. Robert Grant, chief of plastic surgery at Columbia and Cornell - we spoke about "distracted surgery" and also about finding truthful medical information on the internet. Finally, we discussed rejuvenation after chemotherapy. Whew!

Audio podcast from the 7th Annual SDPA Fall Conference in Scottsdale, AZ. This was Session 7 – "Advances in Blue Light Therapy (From Actinic to Acne)" with Ann Lidoski, PA-C. This session is also available as a download on iTunes through the dermcast podcast page*. Click here to visit the [...]

Actinic keratosis and cutaneous squamous cell carcinoma are of increasing importance with aging and increased ultraviolet light exposure in Western societies. Efficient and well-tolerated therapy is still a matter of concern. As with tumours of other organs, new target sites and innovative drugs selectively addressing them are widely looked for. Due to the relevance for DNA synthesis and thus cell proliferation, human DNA polymerase alpha should be such a target, the more so as the three-dimensional structure of the active site has been proposed based on the application of molecular modelling methods and molecular dynamics simulations. The modelled structure of the active site was used for docking nucleotide analogues in order to design selective inhibitors. Consequently, well-fitting thymidine and guanosine analogues were synthesized and tested in vitro for their influence on normal and transformed human keratinocytes. In fact, the combination of modelling studies and in vitro tests allowed us to design antiproliferative and cytotoxic agents which are new drug candidates for the therapy of skin tumours, given the agents are no relevant substrates of nucleotide transporters (MRP-4, MRP-5) expressed by skin cancer cells. Essential kinases for nucleoside activation were detected, too, corresponding with the observed effects of nucleoside analogues. Due to the rather high molecular weight and poor solubility, however, skin penetration should be poor and thus topical therapy may require carriers to improve the uptake. This becomes feasible by lipidic and non-lipidic nanoparticles which can enhance the uptake of lipophilic agents up to 13-fold. Copyright (C) 2010 S. Karger AG, Basel